New England Journal of Medicine publishes positive results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
21
New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder
New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi ® (caplacizumab) for rare blood clotting disorder HERCULES Phase 3 trial met its primary endpoint, demonstrating that treatment with Cablivi resulted in a significantly faster time to platelet count response in patients with acquired thrombotic thrombocytopenic purpura (aTTP) when administered in conjunction with plasma exchange and immunosuppression Cablivi was associated with a significant reduction in aTTP-related death, recurrence, or at least one major thromboembolic event while patients were on treatment, the study's first key secondary endpoint Cablivi was approved by the European Commission in August 2018 PARIS - January 9, 2019 - The New England Journal of Medicine (NEJM) today published positive results of the Phase 3 trial of Cablivi ® (caplacizumab) in adults with acquired thrombotic thrombocytopenic purpura (aTTP). aTTP is a rare, life-threatening autoimmune blood disorder characterized by extensive clot formation in small blood vessels throughout the body, leading to severe thrombocytopenia (very low platelet count), microangiopathic hemolytic anemia (loss of red blood cells through destruction), ischemia (restricted blood supply to parts of the body) and widespread organ damage, especially in the brain and heart. The current treatment for aTTP consists of daily plasma exchange, in which a patient's blood plasma is removed and replaced with donor plasma, and immunosuppression. Even with currently available treatments, patients continue to be at risk of developing acute blood clotting conditions, such as stroke and heart attack, as well as recurrence of disease. Key findings of the HERCULES Phase 3 study of Cablivi include: On the primary endpoint, Cablivi significantly reduced the time to platelet count normalization (p=0.01). At any given time point during the study, patients receiving Cablivi were 1.55 times more likely to achieve normal platelet counts than patients on placebo.   Treatment with Cablivi was associated with a 74 percent reduction in aTTP-related death, recurrence of aTTP, or at least one major thromboembolic event compared with placebo (p<0.001).   During the overall study period, patients receiving Cablivi experienced a significantly lower number of aTTP recurrences (67 percent reduction) compared to placebo (p<0.001).   Refractory disease developed in 0 patients in the Cablivi group versus 3 patients in the placebo group, although this did not reach statistical significance (p=0.06). Normalization of three organ-damage markers (lactate dehydrogenase, cardiac troponin I, and serum creatinine) occurred sooner in patients who received caplacizumab versus placebo (p not tested due to hierarchical statistical testing).   Results showed a clinically meaningful reduction in the use of plasma exchange in patients treated with Cablivi (average 5.8 days; 38 percent reduction) versus placebo (9.4 days), as well as a shorter stay in the intensive care unit (65 percent reduction) and hospital (31 percent reduction). Cablivi demonstrated a safety profile consistent with what has been previously reported and in line with its mechanism of action; this included an increased risk of bleeding. The most frequently reported bleeding-related adverse events were epistaxis and gingival bleeding.   "aTTP is a life-threatening disease, and the current treatment options do not fully halt the extensive clot formation in small blood vessels throughout the body, leaving patients at risk for significant morbidity and early death," said Marie Scully, M.D, professor of hematology at University College London Hospitals, and lead author of the HERCULES study. "These results demonstrate that Cablivi has the potential to address a major unmet medical need and to help those facing the potentially devastating consequences of this disorder." HERCULES is a Phase 3 randomized, double-blind, placebo-controlled study of Cablivi in patients with aTTP. In the study, 145 patients were randomly assigned to Cablivi or placebo in conjunction with plasma exchange and immunosuppression. About Cablivi ® (caplacizumab) Cablivi is an anti-vWF Nanobody, which inhibits the interaction between ultra-large von Willebrand Factor (vWF) multimers and platelets and, therefore, stops the formation and accumulation of the micro-clots that cause the thrombocytopenia, tissue ischemia, and organ dysfunction in aTTP. Cablivi was developed by Ablynx, a Sanofi company. Cablivi was approved by the European Commission in August 2018 for the treatment of adults experiencing an episode of aTTP. It is the first therapeutic specifically indicated for the treatment of aTTP. Additionally, the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application for Cablivi for treatment of patients 18 years of age and older experiencing an episode of aTTP. The target action date for the FDA decision is February 6, 2019.
About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life  
Media Relations Contact Ashleigh Koss Tel.: +1 (908) 981-8745 Ashleigh.Koss@sanofi.com Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45 ir@sanofi.com
Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the absence of guarantee that the product will be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic conditions, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 87

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 272

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work

Updated Category News Views 127

Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 35

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 87

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 21

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 82

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 56

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 35

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 161

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
on>

Top 5 Most Recently Viewed Articles

Virtusa Partners with Wiley to Drive Technological Change

Updated Category News Views 234

Virtusa Partners with Wiley to Drive Technological Change Virtusa Corporation, recognized globally for its leadership in digital business strategy and AI-driven platform engineering, has entered into an exciting partnership with Wiley, a key player in authoritative content and research intelligence. This collaboration aims to foster Wiley's technology transformation over...

Continue Reading
AZZ Inc. Declares Q2 2025 Dividend of $0.17 per Share

Updated Category News Views 67

AZZ Inc. Declares Dividend for the Second Quarter of 2025 AZZ Inc. (NYSE: AZZ), recognized for its leadership in hot-dip galvanizing and coil coating services, has recently notified its shareholders about a significant financial decision. The Board of Directors has approved a second quarter cash dividend amounting to $0.17 per share. This dividend will be allocated to all...

Continue Reading
Tampa General Hospital's Ambulatory Centers Achieve Top Rankings

Updated Category News Views 233

Tampa General Hospital's Ambulatory Centers Recognized The TGH Outpatient Center and TGH Surgery Center at Morsani have earned a prestigious spot among the top five ambulatory surgery centers in the state. Tampa General Hospital (TGH) proudly announces this recognition from a leading publication for the fourth consecutive year. Achievements in Ambulatory Surgery According...

Continue Reading
Norsk Hydro's Resilience Amid Market Challenges: A Detailed Overview

Updated Category News Views 218

Norsk Hydro's Recent Financial Performance Norsk Hydro reported significant financial results for the third quarter, with an adjusted EBITDA of NOK 5,996 million. This showcases a reduction from the NOK 7,367 million recorded in the same period last year, largely attributed to decreased alumina prices and robust NOK dynamics. However, these challenges were mitigated by...

Continue Reading
Top Aerospace and Defense Contractors Shaping the Future

Updated Category News Views 2184

Aerospace and Defense: A Key Industry The aerospace and defense sector is crucial for national security as well as a significant player in the stock market. With the U.S. leading the globe in defense spending, the largest contractors are poised for expansion amid global tensions. Here’s a breakdown of the top 10 largest U.S. defense contractors based on revenue,...

Continue Reading